- Home
- DBL vs NPCE Comparison
DBL vs NPCE Comparison
Compare DBL & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBL
- NPCE
- Stock Information
- Founded
- DBL 2011
- NPCE 1997
- Country
- DBL United States
- NPCE United States
- Employees
- DBL N/A
- NPCE N/A
- Industry
- DBL
- NPCE Medical Specialities
- Sector
- DBL
- NPCE Health Care
- Exchange
- DBL Nasdaq
- NPCE Nasdaq
- Market Cap
- DBL 292.0M
- NPCE 328.8M
- IPO Year
- DBL N/A
- NPCE 2021
- Fundamental
- Price
- DBL $15.42
- NPCE $12.75
- Analyst Decision
- DBL
- NPCE Strong Buy
- Analyst Count
- DBL 0
- NPCE 7
- Target Price
- DBL N/A
- NPCE $17.00
- AVG Volume (30 Days)
- DBL 61.0K
- NPCE 197.1K
- Earning Date
- DBL 01-01-0001
- NPCE 11-04-2025
- Dividend Yield
- DBL 8.67%
- NPCE N/A
- EPS Growth
- DBL N/A
- NPCE N/A
- EPS
- DBL N/A
- NPCE N/A
- Revenue
- DBL N/A
- NPCE $94,864,000.00
- Revenue This Year
- DBL N/A
- NPCE $22.13
- Revenue Next Year
- DBL N/A
- NPCE $6.07
- P/E Ratio
- DBL N/A
- NPCE N/A
- Revenue Growth
- DBL N/A
- NPCE 24.08
- 52 Week Low
- DBL $13.75
- NPCE $6.27
- 52 Week High
- DBL $15.70
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- DBL 45.83
- NPCE 69.34
- Support Level
- DBL $15.28
- NPCE $9.22
- Resistance Level
- DBL $15.56
- NPCE $13.81
- Average True Range (ATR)
- DBL 0.17
- NPCE 0.64
- MACD
- DBL -0.02
- NPCE 0.18
- Stochastic Oscillator
- DBL 27.45
- NPCE 78.22
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.